CD40 binding protein, bispecific conjugate thereof and method of treating cancer
AssigneeStrike Pharma AB
InventorsSara Mangsbo, Helena Persson Lotsholm, Oskar Andersson
Life of this patent
Estimating the term…
Abstract
Provided is a binding protein that binds CD40 and is an agonist thereof. In a particular embodiment the invention provides an agonistic anti-CD40 antibody. Also provided are bispecific conjugates comprising the binding protein, and complexes comprising the bispecific conjugates non-covalently bound to a tag construct comprising an antigen, for antigen delivery to immune cells. Medical uses of the binding proteins, conjugates and complexes of the invention are also provided.
Claims25
A binding protein that specifically binds CD40, wherein said binding protein is an agonist of CD40 and comprises a binding domain of an antibody, the binding domain comprising a heavy chain variable domain and a light chain variable domain, each comprising three complementarity determining domains (CDRs), wherein:
- VLCDR1 has the sequence set forth in SEQ ID NO:
- 1;
- VLCDR2 has the amino acid sequence AAS;
- VLCDR3 has the sequence set forth in SEQ ID NO:
- 3;
- VHCDR1 has the sequence set forth in SEQ ID NO:
- 4;
- VHCDR2 has the sequence set forth in SEQ ID NO:
- 5;
- and
- VHCDR3 has the sequence set forth in SEQ ID NO:
- 6.
Dependencies are inferred from the claim text.